Daniel P. O'Day '97

Chief Operating Officer, Roche Pharmaceuticals

Member, Roche Corporate Executive Committee

 

Daniel O'Day

Daniel O’Day was appointed Chief Operating Officer of the Pharmaceutical Division of Roche in September 2012. Previously, Mr. O’Day was the Chief Operating Officer of the Diagnostics Division starting in January 2010.

Mr. O’Day acquired extensive commercial experience through diverse roles within Roche worldwide. These began at Roche Pharma in the US where he held various commercial and sales roles between 1987 and 1998. Mr. O’Day then moved to the Roche Pharma headquarters in Switzerland where he held leadership roles in Global Marketing and Lifecycle Management until 2001. Subsequently, he was Head of Corporate Planning at Roche Pharma, in Tokyo, Japan between 2001 and 2003, General Manager at Roche Pharma in Denmark between 2003 and 2006, and President of Roche Molecular Diagnostics in California between 2006 and 2009.

Mr. O’Day obtained a Bachelor of Science in Biology from Georgetown University, Washington, DC, in 1986 and an MBA from Columbia University, New York, NY, in 1997.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Charles W. Sorenson MD, President & CEO, Intermountain Healthcare

 

Charles W. Sorenson

Charles W. Sorenson, MD, is the President and Chief Executive Officer of Intermountain Healthcare. He served as its Executive Vice President and Chief Operating Officer from 1998 until he assumed his current position at the end of 2008.

Dr. Sorenson, a graduate of the Cornell University Medical College, is a board certified Urologic Surgeon. He began his practice at LDS Hospital in 1982. His professional activities have included serving as President of the Medical Staff at LDS Hospital, Chairing the Committee on Young Surgeons for the American College of Surgeons, serving as President of the Utah Urologic Society and as Speaker of the House of Delegates of the Utah Medical Association. He is an Adjunct Professor of Surgery at the University of Utah, and served as educational director of the LDS Hospital’s Urologic Residency (a joint program with the University of Utah.)

In addition to his other responsibilities, Dr. Sorenson has had a long-standing interest in clinical process improvement. He helped create the Intermountain Medical Group, an integrated practice of approximately 1,000 physicians employed by Intermountain. He served as the founding chair of the Medical Group Board from 1994 to 1998, when he assumed his full time administrative duties with Intermountain. Under Dr. Sorenson’s leadership, Intermountain Healthcare has implemented a disciplined and system-wide focus on implementation of best clinical practices aimed at producing measurably better outcomes for patients. Similar efforts are being applied to operational best practices, aimed at increasing efficiency and holding down healthcare costs.

Along with his administrative responsibilities Dr. Sorenson has continued to be involved in the practice of surgery. He and his associates Dr. Scott Chidester and Dr. Jay Bishoff focus their practice primarily on urologic oncology. Dr. Sorenson and his wife Sharee have four adult children.

Intermountain Healthcare is an integrated, nonprofit healthcare system serving communities in Utah and southern Idaho. The mission of Intermountain is to provide the highest quality healthcare at the lowest possible cost. The mission includes a commitment to provide care to any individual with a medical need, regardless of ability to pay. Intermountain has been recognized in recent years as a model health system, providing high quality clinical outcomes at overall costs that are among the lowest in the nation.

The Intermountain system consists of three operating groups: Intermountain Health Services, consisting of 22 hospitals in Utah and Idaho, home health agencies, women’s health centers, an integrated network for laboratory services, and psychiatry; Intermountain Medical Group, with about 1,000 employed primary care and secondary care physicians and more than 185 clinics; and SelectHealth, which provides health insurance plans that cover about 550,000 people.